These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 21189647)
1. [New targets in type 2 diabetes therapy]. Hinneburg I Med Monatsschr Pharm; 2010 Aug; 33(8):280-4. PubMed ID: 21189647 [TBL] [Abstract][Full Text] [Related]
2. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. Ghosh RK; Ghosh SM; Chawla S; Jasdanwala SA J Clin Pharmacol; 2012 Apr; 52(4):457-63. PubMed ID: 21543663 [TBL] [Abstract][Full Text] [Related]
3. [Intensive efforts for future antidiabetic agents]. Berne C Lakartidningen; 2010 Nov 10-16; 107(45):2815-9. PubMed ID: 21179868 [No Abstract] [Full Text] [Related]
4. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. Washburn WN J Med Chem; 2009 Apr; 52(7):1785-94. PubMed ID: 19243175 [No Abstract] [Full Text] [Related]
12. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. DeFronzo RA; Davidson JA; Del Prato S Diabetes Obes Metab; 2012 Jan; 14(1):5-14. PubMed ID: 21955459 [TBL] [Abstract][Full Text] [Related]
13. [Oral therapy in type 2 diabetes. Critical evaluation of glitazones]. Lotz N MMW Fortschr Med; 2002 Jan; 144(3-4):48-50. PubMed ID: 11862793 [No Abstract] [Full Text] [Related]
15. The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors. Cangoz S; Chang YY; Chempakaseril SJ; Guduru RC; Huynh LM; John JS; John ST; Joseph ME; Judge R; Kimmey R; Kudratov K; Lee PJ; Madhani IC; Shim PJ; Singh S; Singh S; Ruchalski C; Raffa RB J Clin Pharm Ther; 2013 Oct; 38(5):350-9. PubMed ID: 23909868 [TBL] [Abstract][Full Text] [Related]
16. The importance of beta-cell management in type 2 diabetes. Standl E Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389 [TBL] [Abstract][Full Text] [Related]
17. Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Washburn WN; Poucher SM Expert Opin Investig Drugs; 2013 Apr; 22(4):463-86. PubMed ID: 23452053 [TBL] [Abstract][Full Text] [Related]
18. Insulin resistance and its impact on the approach to therapy of type 2 diabetes. Laakso M Int J Clin Pract Suppl; 2001 Sep; (121):8-12. PubMed ID: 11594246 [TBL] [Abstract][Full Text] [Related]
19. [New therapies for type 2 diabetes mellitus]. Puig-Domingo M; Pellitero S Med Clin (Barc); 2015 Jun; 144(12):560-5. PubMed ID: 25194974 [TBL] [Abstract][Full Text] [Related]
20. Pharmacologic management of the patient with type 2 diabetes. Quinn L Nurs Clin North Am; 2001 Jun; 36(2):217-42, vi. PubMed ID: 11382561 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]